TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04669106

Intervention type: OTHER
Intervention: laboratory clinical trial study
Description: The research stage consisted of two stages, the first stage was the initial screening of the primary data of the research subjects, namely by analyzing food intake including mineral intake data, the diet of the research subjects, mineral and enzyme levels, and data on soil conditions in the area. The second stage was to analyze the relationship between the existing variables so that the most significant relationship was seen between the differences in diet, mineral content, enzyme levels, and soil content between the two groups.
Study: NCT01622049

Intervention type: DEVICE
Intervention: Selective Laser Photocoagulation of Communicating Vessels
Description: Patients will be admitted to Tampa General Hospital. Laboratory tests and anesthesia assessments will be completed. Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. Surgery will be performed preferably under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. Surgery will be performed with standard operative fetoscopy equipment and techniques. A trocar will be introduced in the amniotic cavity of the recipient. An amniotic fluid sample will be obtained for microbiological studies, and genetic analysis for clinical care only. The amniotic fluid will be discarded after analysis. The communicating vessels will be located endoscopically and will be lasered with YAG laser energy. The procedure will be monitored both endoscopically and sonographically. The presence of fetal heart activity will be noted. An amniodrainage of the larger sac may be performed
Study: NCT00910962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW856553
Description: 7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW856553
Description: 15 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01813630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-3002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin®
Study: NCT01431794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225-600mg
Description: Phase I: oral LDE225 (Sonidegib), 600mg daily.~Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225-600mg
Description: Phase I: oral LDE225 (Sonidegib), 600mg daily.~Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.
Study: NCT02580227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
Study: NCT01431794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225-400mg
Description: Phase I: oral LDE225 (Sonidegib), 400mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225-400mg
Description: Phase I: oral LDE225 (Sonidegib), 400mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225-800mg
Description: Phase I: oral LDE225 (Sonidegib), 800mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225-800mg
Description: Phase I: oral LDE225 (Sonidegib), 800mg daily.
Study: NCT00736385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage (Metformin)
Description: metformin XR 2000 mg daily for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 2000 mg daily for 12 months
Study: NCT03267511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica
Description: Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
Study: NCT02580227

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
Study: NCT02131519

Intervention type: PROCEDURE
Intervention: internal jugular vein catheter placement
Study: NCT03554980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: SDF will be applied with a brush.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride varnish
Description: NaF will be applied with a brush
Study: NCT01355796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol
Description: Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: 4 ml of 7 % saline aerosolized twice a day for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: 4 ml of 7 % saline aerosolized twice a day for 2 weeks
Study: NCT03379142

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Faith-Based messages
Description: We will send out faith based text messages on a weekly basis for the one week prior to the start of Ramadan, then twice a day during the Ramadan period that will encourage smoking cessation and continue to encourage change of behavior. The faith-based messages will be incorporated with messages drawn from the Smokefree.gov Mobile Interventions QuitNowTXT Message Library. These messages will be geared towards reminding the smokers that as Ramadan is coming closer they need to consider the effects that smoking may have on their health and should consider taking steps towards quitting.
Study: NCT06508879

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aquacel Ag Surgical®
Description: Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care (sterile gauze and adhesive tape)
Description: Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.
Study: NCT00128713

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medium Dose Prophylactic Platelet Transfusions
Description: 2.2 x 10\^11 platelets per m\^2 BSA
Study: NCT03679780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Arginine
Description: A substrate that is administered to increase endogenous nitric oxide production. The infusion rate will be 2 µl/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NG Nitro L Arginine Methyl Ester
Description: L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG Nitro L Arginine Methyl Ester
Description: L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG Nitro L Arginine Methyl Ester
Description: L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG Nitro L Arginine Methyl Ester
Description: L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitroprusside
Description: SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's
Description: Lactated Ringer will serve as the control site. The infusion rate will be 2 µl/min
Study: NCT02189473

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: external beam radiotherapy (5 x 4 Gy versus 10 x 3 Gy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: external beam radiotherapy (5 x 4 Gy versus 10 x 3 Gy)
Study: NCT02594839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells
Description: Bone marrow will be harvested in healthy donors followed by separation and cultivation of MSCs. Before infusion cells will be suspended in 400 mL saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion of 400 mL saline
Study: NCT00565968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT01622699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Bilirubinometer
Description: If a baby is jaundiced, the ward-nurse will perform a transcutaneous bilirubin measurement. It takes about 5 seconds to perform the measurement at the forehead or sternum of the baby. The device is a validated measurement-tool, which provides us with an estimated serum bilirubin-concentration. This is not an invasive procedure: A light-reflection is used to measure transcutaneous bilirubin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: visual assessment of neonatal jaundice
Description: To detect newborns with jaundice (who will possibly meet the criteria for phototherapy) there have been international guidelines formulated by the American Academy of Pediatrics. The standard of care at the neonatal- and maternity ward of our hospital to detect those newborns is visual assessment according to these guidelines.
Study: NCT01226446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Vitamin D on top of the standard treatment
Study: NCT04262843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: Growth factor therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo hematopoietic cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo TMLI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Immunosuppressive therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Immunosuppressive therapy
Study: NCT01782807

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingectomy or Fimbriectomy
Study: NCT00128713

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lower Dose Prophylactic Platelet Transfusions
Description: 1.1 x 10\^11 platelets per m\^2 BSA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Higher Dose Prophylactic Platelet Transfusions
Description: 4.4 \* 10\^11 platelets per m\^2 BSA
Study: NCT03493789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo FDG-PET

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Undergo SBRT
Study: NCT02973776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 aerosol foam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 aerosol foam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 aerosol foam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100 aerosol foam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 90100 aerosol foam
Study: NCT00453921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Dosage dependent on weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Dosage dependent on weight

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory and Attention Training
Description: Weekly Memory and Attention Training with at home practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory and Attention Training
Description: Weekly Memory and Attention Training with at home practice.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo as both treatments
Description: Placebo capsules and Placebo Memory and Attention Training
Study: NCT02973776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 aerosol foam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dermoval®/Dermovate®
Study: NCT03438292

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPGS emulsified berberine
Description: Two capsules of TPGS/Quillaja extract emulsified berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPGS emulsified berberine
Description: Two capsules of TPGS/Quillaja extract emulsified berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
Study: NCT02973776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dermoval®/Dermovate®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dermoval®/Dermovate®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermoval®/Dermovate®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dermoval®/Dermovate®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dermoval®/Dermovate®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprosone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprosone
Study: NCT03438292

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPGS emulsified berberine
Description: Two capsules of TPGS/Quillaja extract emulsified berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quillaja extract emulsified berberine
Description: Four capsules of Quillaja extract emulsified berberine. Each capsule contains 200 mg berberine. The total amount of berberine throughout is 800 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quillaja extract emulsified berberine
Description: Four capsules of Quillaja extract emulsified berberine. Each capsule contains 200 mg berberine. The total amount of berberine throughout is 800 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quillaja extract emulsified berberine
Description: Four capsules of Quillaja extract emulsified berberine. Each capsule contains 200 mg berberine. The total amount of berberine throughout is 800 mg.
Study: NCT01150812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8165
Description: Oral suspension, 2 mg/mL and 20 mg/mL, single doses
Study: NCT00314951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Description: 200 mg oral capsules two times daily (q12h regimen)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: 125 mg capsules q6hr (4 times a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo to Fidaxomicin
Description: Matching Placebo to Fidaxomicin administered two times daily (intermittently with fidaxomicin dosing)
Study: NCT04428450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deprexis
Description: CBT-based, integrative online self-help program

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deprexis
Description: CBT-based, integrative online self-help program
Study: NCT02928445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-101 35 mg
Description: once daily, oral, 35-mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-101 70 mg
Description: once daily, oral, 35-mg tablets
Study: NCT03403647

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral daily vitamin D
Study: NCT02885766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-114
Study: NCT01940991

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Dose B; dose applied to the lateral canthal lines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Botulinum Toxin Type A, Dose A, dose applied to the lateral canthal lines
Study: NCT02973776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprosone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diprosone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diprosone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprosone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elocon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elocon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elocon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elocon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elocon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elocon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Locoid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Locoid
Study: NCT03267511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP
Description: Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica
Description: Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
Study: NCT02973776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Locoid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Locoid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Locoid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Locoid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 foam vehicle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 foam vehicle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 foam vehicle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEO 90100 foam vehicle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LEO 90100 foam vehicle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 foam vehicle
Study: NCT03267511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP
Description: Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
Study: NCT00928733

Intervention type: DEVICE
Group type: OTHER
Intervention: Gastroduodenoscopy- Intraduodenal intubation
Description: 20 g ethanol diluted up to 10% in tap water